Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Creo Medical Group's Enterprise Value is £117.40 Mil.
Creo Medical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-24.10 Mil. Therefore, Creo Medical Group's EV-to-EBIT ratio for today is -4.87.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Creo Medical Group's Enterprise Value is £117.40 Mil.
Creo Medical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £-20.70 Mil. Therefore, Creo Medical Group's EV-to-EBITDA ratio for today is -5.67.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Creo Medical Group's Enterprise Value is £117.40 Mil.
Creo Medical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £30.80 Mil. Therefore, Creo Medical Group's EV-to-Revenue ratio for today is 3.81.
Creo Medical Group Enterprise Value Historical Data
The historical data trend for Creo Medical Group's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Creo Medical Group's Enterprise Value
For the Medical Devices subindustry, Creo Medical Group's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's Enterprise Value falls into.
Creo Medical Group Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Creo Medical Group's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (LSE:CREO) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Creo Medical Group's current Enterprise Value is £117.40 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Creo Medical Group's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was £-24.10 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Creo Medical Group's current Enterprise Value is £117.40 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Creo Medical Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was £-20.70 Mil.
Creo Medical Group's current Enterprise Value is £117.40 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Creo Medical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was £30.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group Enterprise Value Related Terms
Thank you for viewing the detailed overview of Creo Medical Group's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Creo Medical Group (LSE:CREO) Business Description
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:CREO has been successfully added to your 